Core Viewpoint - The third-party medical testing industry in China has experienced significant growth, particularly during the pandemic, with a market size reaching 630.5 billion yuan in 2022, but is expected to return to pre-pandemic levels in 2023 and stabilize around 388.8 billion yuan in 2024 [1][6]. Group 1: Industry Definition and Business Model - Medical testing is a discipline that utilizes modern physical and chemical methods for clinical diagnosis and treatment [2]. - Independent clinical laboratories (ICLs), also known as third-party medical laboratories, operate independently of hospitals and are licensed by health authorities to provide clinical testing and pathology services [2]. Group 2: Current Development Status - The ICL industry in China began in the 1980s and has become an essential part of the healthcare system due to increasing demand and favorable policies [4]. - The number of ICLs has grown from fewer than 70 in 2009 to an estimated 2,800 by 2024, with projections of reaching 2,845 by 2025 [4]. Group 3: Market Size and Growth Projections - The market size for third-party medical testing services in China was 630.5 billion yuan in 2022, with a significant drop expected in 2023 as pandemic testing demands decrease [6]. - The projected market size for 2024 is 388.8 billion yuan, with special testing accounting for 189.3 billion yuan and general testing for 199.5 billion yuan [6]. - By 2025, the market is expected to grow to approximately 444.9 billion yuan, with special testing at 218.1 billion yuan and general testing at 226.8 billion yuan [6]. Group 4: Industry Chain Structure - The third-party medical testing industry relies on specialized medical services, acting as a substitute for traditional hospital testing departments [8]. - The upstream of the industry includes suppliers of medical devices and testing reagents, while the downstream consists of various healthcare institutions that increasingly outsource testing services [8]. Group 5: Competitive Landscape - The market is characterized by a concentration of major players, with KingMed and Dian Diagnostics holding a combined market share of 36.16% [15]. - KingMed leads the market with a 17.04% share, providing services to over 20,000 medical institutions across 31 provinces and regions [15]. - Smaller third-party testing institutions face challenges due to limited scale and capabilities, leading to market exit pressures since 2015 [15]. Group 6: Financial Performance of Key Players - In 2024, KingMed reported revenues of 6.627 billion yuan, Dian Diagnostics 4.520 billion yuan, and Aidi Kang 2.914 billion yuan, among others [18]. Group 7: Development Trends - The third-party medical testing sector is becoming increasingly important, with regulatory changes posing new challenges [20]. - The industry is expected to focus on technological upgrades and strategic partnerships to enhance profitability and service quality [20]. - Automation, platformization, and intelligence are emerging as key trends in the development of third-party medical laboratories [20].

Company Overview - Shanghai Lanwei Medical Laboratory Co., Ltd. primarily provides third-party medical testing and pathological diagnosis services to various medical institutions, along with sales of well-known domestic and international in vitro diagnostic products and other professional technical support [1] - The main products include in vitro diagnostic product sales and medical diagnostic services [1] Financial Performance - For Q1 2025, the company reported revenue of 351 million yuan, a year-on-year decrease of 19.60% [1] - The net profit for the same period was -8.08 million yuan, representing a year-on-year decline of 854.01% [1] - The gross profit margin stood at 19.95% [1] Shareholder Information - As of March 31, 2025, the number of shareholders for Lanwei Medical was 24,149, a decrease of 562 from the previous count [1] - The average market value of shares held by each shareholder was 352,800 yuan, with an average holding of 27,600 shares [1] Market Metrics - The company's latest closing price was 9.62 yuan, reflecting an increase of 2.45% [1] - The latest price-to-earnings (P/E) ratio (TTM) was -32.49, and the price-to-book (P/B) ratio was 2.34, with a total market capitalization of 3.853 billion yuan [2] - The industry average P/E ratio is 50.80, while the industry median P/E is 36.71 [2]

Group 1 - The core business of Shanghai Lanwei Medical Laboratory Co., Ltd. is to provide third-party medical testing and pathological diagnosis services to various medical institutions, as well as sales of in vitro diagnostic products and other professional technical support [1] - As of the first quarter of 2025, the company reported a revenue of 351 million yuan, a year-on-year decrease of 19.60%, and a net profit of -8.08 million yuan, a year-on-year decrease of 854.01%, with a gross profit margin of 19.95% [1] - The latest closing price of Lanwei Medical is 9.39 yuan, down 1.26%, with a price-to-book ratio of 2.28 and a total market value of 3.761 billion yuan [1] Group 2 - The company is among four institutions holding shares, with a total of 186.16 million shares valued at 1.806 billion yuan [1] - The industry average price-to-earnings (PE) ratio is 49.65, while the median is 36.03, indicating that Lanwei Medical's PE ratio of -31.71 is significantly lower than the industry average [2] - The total market value of the industry is 106.53 billion yuan, with Lanwei Medical's market value being relatively small at 3.761 billion yuan [2]

Core Viewpoint - Shanghai Lanwei Medical Laboratory Co., Ltd. has announced its 2024 annual profit distribution plan, which includes a cash dividend of RMB 79,704,180.00, amounting to RMB 2.00 per 10 shares, excluding shares held in the company's repurchase account [1][2][3] Summary by Sections Annual Profit Distribution Plan - The company will distribute a total cash dividend of RMB 79,704,180.00, with each shareholder receiving RMB 2.00 for every 10 shares held, based on a total share capital of 400,517,000 shares, excluding repurchased shares [1][2] - The remaining undistributed profits will be carried forward to future distributions [1] Key Dates - The record date for the dividend distribution is set for June 6, 2025, and the ex-dividend date is June 9, 2025 [2][3] Dividend Payment Method - Cash dividends will be directly credited to the accounts of shareholders through their securities companies on the ex-dividend date [3] Taxation Details - The company will not withhold individual income tax for certain categories of shareholders, with tax rates varying based on the holding period of the shares [2][3]

证券代码：301060 证券简称：兰卫医学 公告编号：2025-022 上海兰卫医学检验所股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 按公司总股本（含公司回购专户股份，下同）折算的每 10 股现金分红=实际现金分 红总额÷总股本×10 股=79,704,180.00 元÷400,517,000 股×10 股=1.990032 元（保留六位 小数，最后一位直接截取，不四舍五入） 除权除息参考价=股权登记日（2025 年 6 月 6 日）收盘价-0.1990032 元/股（保留七 位小数，最后一位直接截取，不四舍五入） 公司 2024 年年度权益分派方案已经 2025 年 5 月 23 日召开的 2024 年年度股东大 会审议通过，现将权益分派事宜公告如下： 一、股东大会审议通过权益分派方案的情况 1、公司于 2025 年 5 月 23 日召开了 2024 年年度股东大会，审议通过了《关于公司 2024 年度利润分配方案的议案》，公司 2024 年度利润分配方案为：以 2024 年 12 月 31 特别提示： 1 ...

证券代码：301060 证券简称：兰卫医学 公告编号：2025-021 上海兰卫医学检验所股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会不涉及变更前次股东大会已通过的决议的情形。 上海兰卫医学检验所股份有限公司（以下简称"公司"）2024 年年度股东大会于 2025 年 5 月 23 日在公司会议室召开，会议通知已于 2025 年 4 月 28 日以公告形式发出，本 次会议以现场投票与网络投票相结合的方式召开。会议由公司董事长曾伟雄先生主持。 一、会议召开和出席情况 1、会议召开时间： 现场会议召开时间：2025 年 5 月 23 日（星期五）下午 14:30。 网络投票时间：2025 年 5 月 23 日（星期五）。其中 通过深圳证券交易所（以下简称"深交所"）交易系统进行网络投票的具体时间为： 2025 年 5 月 23 日 9:15-9:25，9:30-11:30 和 13:00-15:00； 通过深交所互联网投票系统投票的具体时间为：2 ...

Meeting Announcement - Shanghai Lanwei Medical Laboratory Co., Ltd. will hold its 2024 Annual General Meeting on May 23, 2025, at 14:30 [1][2] - The meeting will combine on-site voting and online voting to facilitate shareholder participation [1][2] Voting Procedures - Shareholders can vote either in person or through a proxy with proper documentation [2][3] - Online voting will be available through the Shenzhen Stock Exchange trading system and internet voting system on May 23, 2025, from 9:15 to 15:00 [1][2] Agenda Items - The meeting will discuss proposals including the application for comprehensive credit limits and guarantees for 2025, and authorization for the board to issue shares through simplified procedures [3][5] - Proposal 11.00 requires a special resolution, needing over 2/3 of the valid votes, while other proposals require a simple majority [5] Registration Requirements - Natural person shareholders must present identification and proof of shareholding; corporate shareholders must provide additional documentation [5][6] - Remote shareholders can register via mail, ensuring their documents arrive by May 20, 2025 [5][6] Contact Information - For inquiries, shareholders can contact Yang Jingjing at the company's office in Shanghai [6]

2、股东大会的召集人：公司董事会 证券代码：301060 证券简称：兰卫医学 公告编号：2025-020 上海兰卫医学检验所股份有限公司 关于召开 2024 年年度股东大会的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 上海兰卫医学检验所股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开 了第四届董事会第三次会议，审议通过了《关于提请召开公司 2024 年年度股东大会的 议案》，决定于 2025 年 5 月 23 日（星期五）召开公司 2024 年年度股东大会。本次股东 大会将采取现场投票与网络投票相结合的方式召开，为方便公司股东行使股东大会表决 权，现将会议相关事项再次提示如下： 一、召开会议的基本情况 1、股东大会届次：2024 年年度股东大会 3、会议召开的合法、合规性：经公司第四届董事会第三次会议审议通过，决定召 开公司 2024 年年度股东大会。本次股东大会的召集、召开符合有关法律、行政法规、 部门规章、规范性文件、深圳证券交易所业务规则和《上海兰卫医学检验所股份有限公 司章程》等规定。 4、会议召开的日期、时间： ...

Group 1 - BYD reported August sales of 174,915 new energy vehicles, a year-on-year increase of 184.84% [1] - Cumulative sales from January to August reached 978,795 units, representing a year-on-year growth of 267.31% [1] - The company sold 5,092 new energy passenger vehicles overseas in August [1] Group 2 - Zhongke Electric's subsidiary plans to establish a joint venture with Chongqing Fudi for the production of anode materials, with a registered capital of 1 billion RMB [2] - Zhongke Electric's subsidiary will contribute 650 million RMB, while Chongqing Fudi will contribute 350 million RMB [2] Group 3 - Yuyuan Group intends to transfer 13% of its shares in Jinhuijiu for approximately 1.937 billion RMB, reducing its stake to 25% [3] - The company plans to further reduce its holdings by more than 5% within the next six months [3] Group 4 - Lizhu Group's recombinant COVID-19 fusion protein vaccine has been included in the emergency use for sequential booster immunization [4] Group 5 - Guanghui Energy plans to repurchase shares worth between 800 million and 1 billion RMB to support employee stock ownership plans [5] Group 6 - Cambrian has launched four cloud-based intelligent chips, although mass sales will require a longer time frame and initial technical service investments [7] Group 7 - LePu Medical has received approval from the China Securities Regulatory Commission for the issuance of Global Depositary Receipts (GDRs) and listing on the Swiss Stock Exchange [9] - The GDR issuance will correspond to no more than 180,458,875 new A-shares [9] Group 8 - Fushi Holdings' subsidiary has entered into an exclusive advertising agency cooperation with the Central Radio and Television Station's automotive channel for three years [10] Group 9 - Guangzhou Port's container throughput in August was 1.981 million TEUs, a year-on-year increase of 2.4% [11] - The total cargo throughput for August was 44.788 million tons, a decrease of 0.6% [11] Group 10 - Ningbo Port expects to complete a container throughput of 3.58 million TEUs in August, a year-on-year increase of 10.2% [12] - The total cargo throughput is projected to decline by 3.0% [12] Group 11 - Ming Tai Aluminum reported a 7% year-on-year decrease in aluminum plate and strip sales in August, while aluminum profile sales increased by 47% [13] Group 12 - Electric Power Investment plans to invest in multiple wind and solar projects, with total static investments of 1.585 billion RMB for wind and 538 million RMB for solar [14] Group 13 - Northeast Pharmaceutical has signed a cooperation agreement with MedAbome for the development of the MAb11-22.1 antibody project [19] Group 14 - New Five Feng plans to acquire equity in Tianxin Seed Industry and several other companies for a total price of approximately 2.208 billion RMB [26] Group 15 - Sumeida's subsidiary plans to transfer 100% equity of eight photovoltaic power station project companies, with an estimated transaction value of 657 million RMB [27] Group 16 - *ST Tongzhou intends to acquire 51% equity in Tongtaiwei, fulfilling the capital contribution obligation of 10.2 million RMB [29] Group 17 - Tianyin Holdings' subsidiary plans to invest 120 million RMB in Xundong Xintong to acquire 40% equity [30] Group 18 - Hainan Haiyao plans to publicly transfer 43% equity in Shanghai Lishengte to attract new investors [31] Group 19 - New Asia Process plans to transfer 7.76% of its shares to Xiangcai New Materials at a price of 5.274 RMB per share [32] Group 20 - Lanwei Medical plans to raise no more than 664 million RMB through a private placement for provincial laboratory construction projects [34] Group 21 - Lida New Materials plans to issue convertible bonds to raise no more than 300 million RMB for a new aluminum material project [35] Group 22 - Gekewei has successfully launched its 12-inch CIS integrated circuit project, achieving over 95% yield [51] Group 23 - Baijin Medical's tricuspid valve ring product has received registration approval [52] Group 24 - Shanghai Pharmaceuticals has received approval to initiate Phase I clinical trials for a recombinant anti-CD20 humanized monoclonal antibody [53] Group 25 - Junda Co. has increased the production capacity of its solar cell production base project from 8GW to 10GW [54]